This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ampel, N. M.
Right arrow Articles by Pappagianis, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ampel, N. M.
Right arrow Articles by Pappagianis, D.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, June 2005, p. 700-704, Vol. 12, No. 6
1071-412X/05/$08.00+0     doi:10.1128/CDLI.12.6.700-704.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Preliminary Evaluation of Whole-Blood Gamma Interferon Release for Clinical Assessment of Cellular Immunity in Patients with Active Coccidioidomycosis

Neil M. Ampel,1,3,4* Daniel K. Nelson,2 Suzette Chavez,2 Kathryn A. Naus,1 Amanda B. Herman,2 Lijin Li,2,4 Keira A. Simmons,5 and Demosthenes Pappagianis5

Medicine and Primary Care Service,1 Research Service, Southern Arizona Veterans Affairs Health Care System,2 Department of Medicine,3 Department of Microbiology and Immunology, University of Arizona, Tucson, Arizona,4 Department of Microbiology and Immunology, University of California at Davis, Davis, California5

Received 22 July 2004/ Returned for modification 6 October 2004/ Accepted 28 March 2005

Assessment of the cellular immune response in coccidioidomycosis has epidemiologic and prognostic importance. Measurement of delayed-type hypersensitivity to skin testing has been used in the past to determine cellular immunity in coccidioidomycosis. However, no skin tests are currently available in the United States. Assay of gamma interferon (IFN-{gamma}) release in whole blood in response to incubation with antigen has been used to assess cellular immunity in tuberculosis. We used a similar assay using the coccidioidal antigen preparation T27K to measure the in vitro cellular immune responses among a cohort of 69 subjects with active coccidioidomycosis. IFN-{gamma} release was bimodal, with concentrations above and below 5 IU/ml. Using multivariate logistic regression, underlying disease and disseminated or chronic pulmonary coccidioidomycosis was significantly associated with the release of IFN-{gamma} at a concentration of <5 IU/ml (P = 0.02 or 0.05, respectively). In addition, the release IFN-{gamma} concentration was <5 IU/ml in all subjects with a clinical severity score of ≥6 (P = 0.02). The release IFN-{gamma} concentration correlated with expression of CD69 on T lymphocytes in an in vitro assay using T27K as the antigen (Spearman's rho = 0.59; P < 0.01). These results suggest that the IFN-{gamma} release assay with T27K as the antigen may be a useful clinical test for assessing cellular immunity in patients with active coccidioidomycosis.

* Corresponding author. Mailing address: Medicine and Primary Care (1-111), Southern Arizona Veterans Affairs Health Care System, 3601 S. Sixth Avenue, Tucson, AZ 85723. Phone: (520) 792-1450, ext. 6186. Fax: (520) 629-1861. E-mail: nampel{at}u.arizona.edu.

Clinical and Diagnostic Laboratory Immunology, June 2005, p. 700-704, Vol. 12, No. 6
1071-412X/05/$08.00+0     doi:10.1128/CDLI.12.6.700-704.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.





Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»